Citrullinated Histone H3 (Cit H3) in Septic Shock
    3.
    发明申请
    Citrullinated Histone H3 (Cit H3) in Septic Shock 审中-公开
    柑橘酸组蛋白H3(Cit H3)在脓毒性休克

    公开(公告)号:US20140057829A1

    公开(公告)日:2014-02-27

    申请号:US13981032

    申请日:2012-02-01

    IPC分类号: G01N33/68

    摘要: Methods of diagnosing sepsis, severe sepsis, or septic shock and predicting prognosis in subjects with septic shock, based on levels of citrullinated histone H3 (Cit H3) in the subject, e.g., in a sample comprising serum (e.g., whole blood, serum, or plasma), cerebrospinal fluid, urine, saliva, or peritoneal fluid from the subject.

    摘要翻译: 基于受试者的瓜氨酸化组蛋白H3(Cit H3)的水平,例如在含有血清(例如全血,血清,血清,血清,血清, 或血浆),脑脊液,尿液,唾液或腹膜液。

    INTEGRATION OF A PRIVATE CELLULAR SYSTEM INTO A UNIFIED COMMUNICATIONS SOLUTION
    4.
    发明申请
    INTEGRATION OF A PRIVATE CELLULAR SYSTEM INTO A UNIFIED COMMUNICATIONS SOLUTION 失效
    将私有细胞系统整合到统一的通信解决方案中

    公开(公告)号:US20100080214A1

    公开(公告)日:2010-04-01

    申请号:US12242349

    申请日:2008-09-30

    IPC分类号: H04L12/66

    摘要: In one embodiment, a communication system includes a private cellular base station subsystem to communicate, using a cellular radio frequency air radio interface, with home cellular wireless devices and visiting cellular wireless devices located within a coverage area associated with the private cellular base station subsystem. Each of the home cellular wireless devices having associated therewith (i) a public cellular number from a home public land mobile network, and (ii) a private cellular number from a private network associated with the communication system. The communication system further includes a private cellular switching subsystem to provide cellular switching functionality within the private network for the home cellular wireless devices in connection with sessions that are associated with the respective private cellular numbers of the respective home cellular wireless devices. The communication system further includes unified communications (UC) functionality to interface the private cellular switching subsystem to a unified communications server in order to provide unified communications services using the home cellular wireless devices.

    摘要翻译: 在一个实施例中,通信系统包括专用蜂窝基站子系统,用于使用蜂窝无线电频率无线电接口与位于与专用蜂窝基站子系统相关联的覆盖区域内的家庭蜂窝无线设备和访问蜂窝无线设备进行通信。 每个家庭蜂窝无线设备具有与其相关联的(i)来自家庭公共陆地移动网络的公共蜂窝号码,以及(ii)来自与通信系统相关联的专用网络的专用蜂窝号码。 通信系统还包括私有蜂窝交换子系统,用于为家庭蜂窝无线设备提供专用网络内的蜂窝交换功能,该蜂窝交换子系统与相应家庭蜂窝无线设备的相应专用蜂窝号码相关联的会话结合。 通信系统还包括统一通信(UC)功能,以将私有蜂窝交换子系统接入统一通信服务器,以便使用家庭蜂窝无线设备提供统一的通信服务。

    CONDITIONAL SUPERAGONIST CTL LIGANDS FOR THE PROMOTION OF TUMOR-SPECIFIC CTL RESPONSES
    6.
    发明申请
    CONDITIONAL SUPERAGONIST CTL LIGANDS FOR THE PROMOTION OF TUMOR-SPECIFIC CTL RESPONSES 有权
    用于促进肿瘤特异性CTL应答的条件超级CTL配体

    公开(公告)号:US20130108657A1

    公开(公告)日:2013-05-02

    申请号:US13696303

    申请日:2011-11-10

    IPC分类号: A61K39/00

    摘要: What is described is a novel genetic screen, involving recombinant technology and class I antigen cross-presentation, to search for supraoptimal superagonists of the 27L MART-1 mutant selecting for single amino acid substitution mutants of 27L that activate human antigen-specific CTL clones recognizing the wild-type MART-126-35 epitope. Three novel mutant epitopes are identified with superagonist properties that are functionally superior to 27L. The ability of a given analog to act as superagonist varies among patients. Also described is the use of methods to establish panels of potential superagonist APLs to individualize tumor peptide vaccines among patients. The methodology is replicated to identify APL to NY-ESO-1157-165 and NY-ESO-1157-170 tumor epitopes. A general method is described that is useful to produce a tumor vaccine to any tumor epitope.

    摘要翻译: 描述的是一种新型遗传筛选,涉及重组技术和I类抗原交叉呈递,以搜索27L MART-1突变体的超最佳超抗体,其选择27L的单个氨基酸取代突变体,其激活识别的人抗原特异性CTL克隆 野生型MART-126-35表位。 三个新的突变体表位被鉴定为具有功能优于27L的超强度属性。 给予类似物作为超级运动员的能力因患者而异。 还描述了使用方法来建立潜在的超级拮抗剂APL的小组,以在患者之间个体化肿瘤肽疫苗。 该方法被复制以鉴定到NY-ESO-1157-165和NY-ESO-1157-170肿瘤表位的APL。 描述了可用于产生任何肿瘤表位的肿瘤疫苗的一般方法。

    BIOMARKERS OF HEMORRHAGIC SHOCK
    8.
    发明申请
    BIOMARKERS OF HEMORRHAGIC SHOCK 有权
    生物标记的HEMORRHAGIC SHOCK

    公开(公告)号:US20130149713A1

    公开(公告)日:2013-06-13

    申请号:US13696530

    申请日:2011-05-11

    IPC分类号: G01N33/68

    摘要: Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS).

    摘要翻译: 使用角质形成细胞趋化因子(KC)/人生长调节癌基因(GRO)(KC / GRO),载脂蛋白A2(APOA2),血管紧张素原r(AGT),甲状腺球蛋白(TG),去整合素和金属蛋白酶结构域的蛋白17 (ADAM17),阴离子胰蛋白酶-1(PRSS1),补体C4(C4A),透明带精子结合蛋白1(ZP1),神经蛋白-2(NRP2),溶质载体家族13成员2(SLC13A2),胰高血糖素样肽 2受体(GLP2R),脂肪瘤高迁移率组蛋白质同种型IC(HMGIC)融合伴侣蛋白4(LHFPL4)和克劳丁-3(CLDN3)作为诊断和预后的生物标志物,并用于监测治疗出血性功能 休克(HS)。

    Biomarkers of hemorrhagic shock
    10.
    发明授权
    Biomarkers of hemorrhagic shock 有权
    出血性休克的生物标志物

    公开(公告)号:US09435813B2

    公开(公告)日:2016-09-06

    申请号:US13696530

    申请日:2011-05-11

    摘要: Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS).

    摘要翻译: 使用角质形成细胞趋化因子(KC)/人生长调节癌基因(GRO)(KC / GRO),载脂蛋白A2(APOA2),血管紧张素原r(AGT),甲状腺球蛋白(TG),去整合素和金属蛋白酶结构域的蛋白17 (ADAM17),阴离子胰蛋白酶-1(PRSS1),补体C4(C4A),透明带精子结合蛋白1(ZP1),神经蛋白-2(NRP2),溶质载体家族13成员2(SLC13A2),胰高血糖素样肽 2受体(GLP2R),脂肪瘤高迁移率组蛋白质同种型IC(HMGIC)融合伴侣蛋白4(LHFPL4)和克劳丁-3(CLDN3)作为诊断和预后的生物标志物,并用于监测治疗出血性功能 休克(HS)。